Clarity expands its pipeline with a novel optimised FAP-targeted radiopharmaceutical
Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for ...